Shionogi & Co., Ltd. – Product Pipeline Review – 2013

Publisher Name :
Date: 31-Jul-2013
No. of pages: 78
Inquire Before Buying

Shionogi & Co., Ltd. – Product Pipeline Review – 2013


Global Markets Direct’s pharmaceuticals report, “Shionogi & Co., Ltd. – Product Pipeline Review – 2013″ provides data on the Shionogi & Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Shionogi & Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Shionogi & Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.


- Shionogi & Co., Ltd. – Brief Shionogi & Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Shionogi & Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Shionogi & Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Shionogi & Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Shionogi & Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Shionogi & Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Shionogi & Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Shionogi & Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Shionogi & Co., Ltd. and identify potential opportunities in those areas.

Shionogi & Co., Ltd. – Product Pipeline Review – 2013

Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 7
Shionogi & Co., Ltd. Snapshot 8
Shionogi & Co., Ltd. Overview 8
Key Information 8
Key Facts 8
Shionogi & Co., Ltd. - Research and Development Overview 9
Key Therapeutic Areas 9
Shionogi & Co., Ltd. - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Shionogi & Co., Ltd. - Pipeline Products Glance 17
Shionogi & Co., Ltd. - Late Stage Pipeline 17
Phase III Products/Combination Treatment Modalities 17
Shionogi & Co., Ltd. Clinical Stage Pipeline Products 18
Phase II Products/Combination Treatment Modalities 18
Phase I Products/Combination Treatment Modalities 19
Shionogi & Co., Ltd. - Early Stage Pipeline Products 20
Preclinical Products/Combination Treatment Modalities 20
Discovery Products/Combination Treatment Modalities 21
Shionogi & Co., Ltd. - Drug Profiles 22
(irbesartan + trichlormethiazide) 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
(lidocaine + prilocaine) 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
39-f 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Actair 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Benzimidazole Derivative 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Beta-Secretase Inhibitor 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Compound-18e 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
doripenem 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
duloxetine hydrochloride DR 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
guanfacine hydrochloride ER 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
interferon gamma-1a 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Japanese Cedar Pollen Tablet 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
lisdexamfetamine dimesylate 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
lusutrombopag 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
naldemedine 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ospemifene 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
oxycodone hydrochloride 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
P2X3 Receptor Antagonist 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Peptide Cocktail Vaccine 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
prednisolone acetate 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
S-117957 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
S-120083 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
S-222611 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
S-234462 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
S-288310 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
S-488210 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
S-488410 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
S-555739 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
S-556971 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
S-646240 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
S-649266 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
S-707106 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
velneperit 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Shionogi & Co., Ltd. - Pipeline Analysis 55
Shionogi & Co., Ltd. - Pipeline Products by Therapeutic Class 55
Shionogi & Co., Ltd. - Pipeline Products By Target 59
Shionogi & Co., Ltd. - Pipeline Products by Route of Administration 60
Shionogi & Co., Ltd. - Pipeline Products By Mechanism of Action 61
Shionogi & Co., Ltd. - Recent Pipeline Updates 63
Shionogi & Co., Ltd. - Dormant Projects 69
Shionogi & Co., Ltd. - Discontinued Pipeline Products 70
Discontinued Pipeline Product Profiles 70
ADX-415 70
clonidine hydrochloride 70
doripenem 70
lusutrombopag 71
S-444823 71
S-5751 71
S-777469 71
S-8510 71
teceleukin 72
velneperit 72
Shionogi & Co., Ltd. - Company Statement 73
Shionogi & Co., Ltd. - Locations And Subsidiaries 74
Head Office 74
Other Locations & Subsidiaries 74
Shionogi & Co., Ltd. - Key Manufacturing Facilities 76
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 78
Disclaimer 78

List of Tables
Shionogi & Co., Ltd., Key Information 8
Shionogi & Co., Ltd., Key Facts 8
Shionogi & Co., Ltd. - Pipeline by Indication, 2013 12
Shionogi & Co., Ltd. - Pipeline by Stage of Development, 2013 14
Shionogi & Co., Ltd. - Monotherapy Products in Pipeline, 2013 15
Shionogi & Co., Ltd. - Combination Treatment Modalities in Pipeline, 2013 16
Shionogi & Co., Ltd. - Phase III, 2013 17
Shionogi & Co., Ltd. - Phase II, 2013 18
Shionogi & Co., Ltd. - Phase I, 2013 19
Shionogi & Co., Ltd. - Preclinical, 2013 20
Shionogi & Co., Ltd. - Discovery, 2013 21
Shionogi & Co., Ltd. - Pipeline By Therapeutic Class, 2013 56
Shionogi & Co., Ltd. - Pipeline By Target, 2013 59
Shionogi & Co., Ltd. - Pipeline By Route of Administration, 2013 60
Shionogi & Co., Ltd. - Pipeline Products By Mechanism of Action, 2013 61
Shionogi & Co., Ltd. - Recent Pipeline Updates, 2013 63
Shionogi & Co., Ltd. - Dormant Developmental Projects,2013 69
Shionogi & Co., Ltd. - Discontinued Pipeline Products, 2013 70
Shionogi & Co., Ltd., Other Locations 74
Shionogi & Co., Ltd., Subsidiaries 75
Shionogi & Co., Ltd., Key Manufacturing Facilities 76

List of Figures
Shionogi & Co., Ltd. - Pipeline by Indication, 2013 11
Shionogi & Co., Ltd. - Pipeline by Stage of Development, 2013 14
Shionogi & Co., Ltd. - Monotherapy Products in Pipeline, 2013 15
Shionogi & Co., Ltd. - Combination Treatment Modalities in Pipeline, 2013 16
Shionogi & Co., Ltd. - Pipeline By Therapeutic Class, 2013 55
Shionogi & Co., Ltd. - Pipeline By Route of Administration, 2013 60
Shionogi & Co., Ltd. - Pipeline Products By Mechanism of Action, 2013 61
  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • Aortic Stent Grafts – Current and Future Players
    Published: 29-Oct-2014        Price: US $3500 Onwards        Pages: 106
    Aortic stent grafts are most commonly used to reinforce a weak spot in an artery, which is known as an aneurysm. The stent grafts are designed to seal tightly with the patient’s native artery above and below the aneurysm, and are used to treat abdominal aortic aneurysms as well as thoracic aortic aneurysms. Aortic aneurysms, as opposed to aneurysms found elsewhere in the body, are potentially very serious, as a burst aorta results in massive internal bleeding that can be fatal unless treated r......
  • Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma
    Published: 29-Oct-2014        Price: US $6995 Onwards        
    Large Degree of Innovation in NSCLC Pipeline The NSCLC pipeline currently has 389 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. Where the market comprises primarily ineffective chemotherapies that target tubulin or DNA replication, the pipeline shows an incredibly diverse range of therapies targeting multiple signaling pathways and molecules integral to cancer development. Thi......
  • Egypt Pharmaceuticals and Healthcare Report Q4 2014
    Published: 29-Oct-2014        Price: US $1295 Onwards        Pages: 126
    BMI View: Egypt's relative political stability will lead to a pickup in growth over the coming quarters, increasing the attractiveness of the pharmaceutical market - for which our forecast has been revised slightly upwards. The government's increased emphasis on developing the pharmaceutical sector and the announced expansion of the Medicare healthcare programme are positive developments this quarter. The challenges faced by pharmaceutical companies wishing to operate in the market are the c......
  • Indonesia Pharmaceuticals and Healthcare Report Q4 2014
    Published: 29-Oct-2014        Price: US $1295 Onwards        Pages: 142
    BMI View: Indonesia is one of the most promising markets for the pharmaceutical and healthcare companies in South East Asia. The country's large population, positive economic outlook and considerable disease burden bode well for growth in demand for drugs, medical devices and healthcare services. The ongoing implementation of the universal healthcare scheme in Indonesia coupled with the impending launch of the ASEAN Economic Community will provide growth opportunities for pharmaceutical firm......
  • Moldova Pharmaceuticals and Healthcare Report Q4 2014
    Published: 29-Oct-2014        Price: US $1295 Onwards        Pages: 93
    BMI View: The Moldovan pharmaceutical market presents limited opportunities for investors, given the market's total size and its reliance on out-of-pocket payments. The country's economic outlook, which is defined by its relations with Russia and the EU, will play a significant role in how the market grows over the coming years. Headline Expenditure Projections ? Pharmaceuticals: MDL2.73bn (USD214mn) in 2013 to MDL2.9bn (USD226mn) in 2014; +5.7% in local currency terms and +5.4% in US doll......
  • Sri Lanka Pharmaceuticals and Healthcare Report Q4 2014
    Published: 29-Oct-2014        Price: US $1295 Onwards        Pages: 81
    BMI View: Sri Lanka's pharmaceutical sector has received investment from domestic and foreign - notably Indian - investors in recent years, as economic growth has picked up and the government focused on improving the domestic pharmaceutical sector. We therefore expect that pharmaceutical and healthcare sector growth will outpace economic growth over the five-year forecast period. Improved relations with India, after the country abstained from voting on the UNHCR resolution, are likely to spu......
  • 2014 Deep Research Report on Global and China Nalbuphine HCL Industry
    Published: 28-Oct-2014        Price: US $2200 Onwards        Pages: 121
    This is a professional and depth research report on Global and China Nalbuphine HCL industry. The report firstly introduced Nalbuphine HCL basic information included Nalbuphine HCL definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Nalbuphine HCL industry policy and plan, Nalbuphine HCL product specification, manufacturing process,......
  • 2014 Deep Research Report on Global and China Naltrexone HCL Industry
    Published: 28-Oct-2014        Price: US $2200 Onwards        Pages: 138
    This is a professional and depth research report on Global Naltrexone HCL industry. The report firstly introduced Naltrexone HCL basic information included Naltrexone HCL definition classification application industry chain structure industry overview; international market analysis, China domestic market analysis. Global Regional (such as US Europe Asia China Japan etc regions) Global Leading Suppliers, different type products, different applications etc Naltrexone HCL production and market shar......
  • RNA Interference Screening Trends 2014
    Published: 27-Oct-2014        Price: US $2500 Onwards        Pages: 53
    Executive Summary This market report summarizes the results of HTStec’s industry-wide global web-based benchmarking survey on RNA interference (RNAi) screening and gene silencing carried out in October 2014. The survey was initiated by HTStec as part of its tracking of emerging life science marketplaces and to update our previous report in siRNA screening (published September 2012). The questionnaire was compiled to meet the needs, requirements and interests of the RNAi screening vendo......
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs